UY31044A1 - Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno - Google Patents

Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno

Info

Publication number
UY31044A1
UY31044A1 UY31044A UY31044A UY31044A1 UY 31044 A1 UY31044 A1 UY 31044A1 UY 31044 A UY31044 A UY 31044A UY 31044 A UY31044 A UY 31044A UY 31044 A1 UY31044 A1 UY 31044A1
Authority
UY
Uruguay
Prior art keywords
combination
cancer
progesterone
antiestrogen
brca
Prior art date
Application number
UY31044A
Other languages
English (en)
Inventor
Daniel Korr
Jens Hoffmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY31044A1 publication Critical patent/UY31044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso individual del antagonista del receptor de progesterona 11B.(4-acetilfenil) -17B-hidroxi-17a-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona, o un derivado o un análogo de éste como fármaco, para la profilaxis y el tratamiento del cáncer de mama mediado por BRCA1 o BRCA2, y combinacion que comprende el antagonista del receptor de progesterona mencionado, o un derivado o un análogo de éste para uso farmacéutico, con al menos un antiestrogeno puro, para la profilaxis y el tratamiento del cáncer de mama mediado por BRCA1 o BRCA2, el cáncer de ovario, el cáncer de endometrio, el cáncer gástrico, el cáncer colorrectal, la endometriosis,el mieloma, el mioma y el meningioma.
UY31044A 2007-04-23 2008-04-22 Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno UY31044A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07090083 2007-04-23
US91437207P 2007-04-27 2007-04-27

Publications (1)

Publication Number Publication Date
UY31044A1 true UY31044A1 (es) 2008-11-28

Family

ID=39671992

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31044A UY31044A1 (es) 2007-04-23 2008-04-22 Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno

Country Status (11)

Country Link
US (1) US20090029954A1 (es)
EP (1) EP2136796A2 (es)
JP (1) JP2010524997A (es)
AR (1) AR066234A1 (es)
CA (1) CA2683809A1 (es)
CL (1) CL2008001148A1 (es)
PA (1) PA8777301A1 (es)
PE (1) PE20090152A1 (es)
TW (1) TW200904451A (es)
UY (1) UY31044A1 (es)
WO (1) WO2008128791A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231292A1 (en) * 2012-03-02 2013-09-05 Wei Zhou Synergistic anti-proliferation activity of TAS-108 with mTOR inhibitors against cancer cells
EP3323417A4 (en) * 2015-07-14 2019-06-05 Nobelpharma Co., Ltd. PARTIAL ESTROGEN RECEPTOR BETA AGONIST WITH ESTROGEN RECEPTOR-ALPHA-INHIBITING EFFECT AND THERAPEUTIC AGENT AGAINST GYNECOLOGICAL DISORDERS THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DK1326617T3 (da) * 2000-10-18 2006-12-18 Schering Ag Anvendelse af 11beta- (acetylphenyl) -17beta-hydroxy-17alfa- (1,1,2,2-pentafluorethyl) estra-4,9-dien-3-on til fremstilling af et medikament til behandling af brystcancer, ovariecancer, endometrisk caner, myeloma og meningeom
SK287124B6 (sk) * 2000-10-18 2009-12-07 Schering Aktiengesellschaft Použitie antiprogestínu na prípravu liečiva
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
EP2136796A2 (en) 2009-12-30
CA2683809A1 (en) 2008-10-30
US20090029954A1 (en) 2009-01-29
WO2008128791A2 (en) 2008-10-30
WO2008128791A3 (en) 2008-12-11
PE20090152A1 (es) 2009-04-30
PA8777301A1 (es) 2008-11-19
AR066234A1 (es) 2009-08-05
JP2010524997A (ja) 2010-07-22
CL2008001148A1 (es) 2008-11-03
TW200904451A (en) 2009-02-01

Similar Documents

Publication Publication Date Title
MX2022005780A (es) Moduladores de receptores estrogenicos.
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
HN2012000137A (es) Derivados de 17 - hidroxi - 17 - pentafluoroetil - estra - 4, 9(10) - dien - 11 - arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
ATE469895T1 (de) Cgrp-rezeptorantagonisten
IL192816A (en) Permanent pattern erasers, pharmaceutical preparations containing them and their use in the preparation of drugs
TN2011000172A1 (en) Therapeutic antiviral peptides
BR112014016635B8 (pt) composto, composição, e, uso de um composto
CL2011000570A1 (es) Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras.
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
NZ771719A (en) Selective estrogen receptor degraders
MX2023000677A (es) Compuestos moduladores de receptor de estrogeno.
AR070456A1 (es) Combinacion que comprende paclitaxel para el tratamiento de cancer de ovario y su uso
CO6341625A2 (es) Derivados de indol como agentes anticáncer
AR066893A1 (es) Uso del factor de crecimiento de fibroblastos 7 (fgf7) y del receptor fgfr2b como biomarcadores
UY31044A1 (es) Antagonista del receptor de progesterona para usar en brca, solo o en combinacion con un antiestrogeno
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
CL2008001322A1 (es) Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2017002890A1 (es) Paneles de yeso
CL2008001147A1 (es) Combinacion farmaceutica que comprende 11b-(4-acetilfenil)-17b-hidroxi-17 (1,1,2,2,2-pentafluoroetil) estra-4,9-dien-3-ona junto con al menos un antiestrogeno no esteroidal puro; y uso para la profilaxis o el tratamientodel cancer mediado por brca1 o brca2.
PA8777501A1 (es) Combinación de antagonista del receptor de progesterona con antiestrógenos no esteroidales para usar en enfermedades mediadas por brca
MX2021003500A (es) Uso de un inhibidor de un transportador de la familia ent en el tratamiento del cáncer y su combinación con un antagonista del receptor de adenosina.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171005